Suppliers and packagers for generic pharmaceutical drug: NITROGLYCERIN

NITROGLYCERIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pohl Boskamp	NITROLINGUAL	nitroglycerin	AEROSOL;SUBLINGUAL	018705	NDA	INDEPENDENCE PHARMACEUTICALS, LLC	21724-100-41	1 BOTTLE, SPRAY in 1 CARTON (21724-100-41) / 200 SPRAY in 1 BOTTLE, SPRAY	2024-12-02
Pohl Boskamp	NITROLINGUAL	nitroglycerin	AEROSOL;SUBLINGUAL	018705	NDA	INDEPENDENCE PHARMACEUTICALS, LLC	21724-100-50	1 BOTTLE, SPRAY in 1 CARTON (21724-100-50) / 60 SPRAY in 1 BOTTLE, SPRAY	2024-12-02
Pohl Boskamp	NITROLINGUAL	nitroglycerin	AEROSOL;SUBLINGUAL	018705	NDA AUTHORIZED GENERIC	Allegis Pharmaceuticals, LLC	28595-120-12	1 BOTTLE in 1 CARTON (28595-120-12) / 200 SPRAY in 1 BOTTLE	2019-07-01
Pohl Boskamp	NITROLINGUAL	nitroglycerin	AEROSOL;SUBLINGUAL	018705	NDA AUTHORIZED GENERIC	Allegis Pharmaceuticals, LLC	28595-120-49	1 BOTTLE in 1 CARTON (28595-120-49) / 60 SPRAY in 1 BOTTLE	2019-07-01
Pohl Boskamp	NITROLINGUAL	nitroglycerin	AEROSOL;SUBLINGUAL	018705	NDA	Allegis Pharmaceuticals, LLC	28595-550-12	1 BOTTLE, SPRAY in 1 CARTON (28595-550-12) / 200 SPRAY in 1 BOTTLE, SPRAY	2019-07-01
Pohl Boskamp	NITROLINGUAL	nitroglycerin	AEROSOL;SUBLINGUAL	018705	NDA	Allegis Pharmaceuticals, LLC	28595-550-49	1 BOTTLE, SPRAY in 1 CARTON (28595-550-49) / 60 SPRAY in 1 BOTTLE, SPRAY	2019-07-01

Nitroglycerin Drug Suppliers

Last updated: February 19, 2026

This report details key suppliers for the pharmaceutical drug nitroglycerin, focusing on active pharmaceutical ingredient (API) manufacturers and their regulatory status. The landscape for nitroglycerin API is characterized by established producers with extensive experience in handling explosive precursors and a significant portion of global supply originating from Asia.

Who are the Primary API Manufacturers for Nitroglycerin?

The production of nitroglycerin API is a specialized process due to the inherent instability and explosive nature of the compound. Manufacturers require stringent safety protocols, specialized facilities, and regulatory compliance. Key entities involved in the supply chain include:

• Apotex Inc.: Based in Canada, Apotex is a significant player in generic pharmaceuticals and manufactures various APIs, including those for cardiovascular drugs. While specific details on their nitroglycerin API production volume are proprietary, their broad portfolio indicates a capability. [1]
• Amneal Pharmaceuticals LLC: This U.S.-based company operates multiple manufacturing facilities and is a major producer of generic APIs and finished dosage forms. Amneal's capabilities encompass complex chemical synthesis, which would be applicable to nitroglycerin. [2]
• Hikma Pharmaceuticals PLC: A global pharmaceutical company headquartered in the UK, Hikma manufactures and markets a wide range of branded and generic products. They have a substantial API development and manufacturing footprint, particularly in the United States and Portugal. [3]
• Takeda Pharmaceutical Company Limited: While Takeda is a large, research-focused pharmaceutical company, it also has manufacturing operations for established drugs and their components. Their historical presence in cardiovascular medicine suggests potential involvement in nitroglycerin API supply, either directly or through acquired entities. [4]
• Aarti Industries Limited: This Indian company is a prominent manufacturer of specialty chemicals and pharmaceuticals, with a significant focus on nitroaromatics and other hazardous chemicals. Aarti Industries is known for its expertise in nitration processes, a core element in nitroglycerin synthesis. [5]
• Sree Krishna Pharma Ltd.: Another Indian manufacturer, Sree Krishna Pharma specializes in APIs and intermediates, with a portfolio that includes cardiovascular drugs. Their capabilities in complex chemical synthesis and regulatory compliance are critical for nitroglycerin production. [6]
• R.B. Laboratories Pvt. Ltd.: Based in India, this company manufactures APIs and intermediates. Their product list often includes cardiovascular agents, and their facilities are designed to handle specific chemical processes required for APIs like nitroglycerin. [7]

These companies often operate under strict Good Manufacturing Practices (GMP) guidelines and are subject to inspections by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

What is the Regulatory Landscape for Nitroglycerin API Production?

The production and handling of nitroglycerin are subject to stringent regulations due to its classification as an explosive substance and its use as a critical medication. Key regulatory considerations include:

• U.S. Food and Drug Administration (FDA): Manufacturers of nitroglycerin API intended for sale in the United States must comply with FDA regulations, including cGMP (current Good Manufacturing Practices). Facilities are subject to inspection, and drug master files (DMFs) must be submitted for review. [8] The FDA also monitors drug shortages, which can be relevant if supply chain disruptions occur.
• European Medicines Agency (EMA): For APIs to be used in medicinal products marketed in the European Union, manufacturers must adhere to EMA guidelines and obtain a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM), or comply with equivalent national requirements. [9]
• DEA and ATF Regulations (United States): Because nitroglycerin is a highly unstable explosive, its precursor chemicals and manufacturing processes are subject to oversight by the Drug Enforcement Administration (DEA) and the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) for security and safety compliance, even when produced for pharmaceutical use. [10]
• International Narcotics Control Board (INCB) and Precursor Chemical Regulations: While nitroglycerin itself is not typically a controlled substance under the INCB’s purview, its synthesis often involves precursor chemicals that may be regulated internationally or nationally to prevent diversion for illicit purposes.
• Explosives Safety Regulations: Manufacturers must comply with national and international regulations governing the safe storage, handling, and transportation of explosive materials. This includes adherence to standards set by organizations like the United Nations Economic Commission for Europe (UNECE) for the transport of dangerous goods. [11]

The regulatory burden is significant, requiring substantial investment in safety infrastructure, quality control systems, and documentation. This often limits the number of manufacturers capable of producing nitroglycerin API reliably.

What are the Key Supply Chain Considerations for Nitroglycerin?

The supply chain for nitroglycerin API presents several unique challenges and considerations:

• Raw Material Sourcing: Key raw materials for nitroglycerin synthesis include glycerol and nitric acid. The availability and quality of these precursors are critical. Nitric acid production itself is energy-intensive and subject to market fluctuations.
• Manufacturing Complexity and Safety: The nitration process to create nitroglycerin is inherently hazardous. Manufacturers must employ highly specialized equipment and personnel trained in handling explosive materials. This can limit the number of potential manufacturing sites and increase lead times.
• Storage and Transportation: Due to its instability, nitroglycerin API requires specialized storage facilities that are temperature-controlled and explosion-proof. Transportation is also subject to strict hazardous materials regulations, increasing logistical costs and complexity.
• Geopolitical and Economic Factors: A significant portion of global API manufacturing, including that for many cardiovascular drugs, is concentrated in Asia, particularly India and China. Geopolitical tensions, trade policies, and economic conditions in these regions can impact supply chain stability. For example, environmental regulations in China have historically led to temporary shutdowns of chemical plants, affecting global supply. [12]
• Drug Master Files (DMFs): Pharmaceutical companies relying on external API suppliers must ensure their suppliers have robust DMFs filed with regulatory agencies. This documentation is essential for their own drug product applications and requires ongoing maintenance and updates from the API manufacturer.
• Quality Control and Assurance: Consistent quality of nitroglycerin API is paramount for patient safety and drug efficacy. Robust quality control measures at every stage of production, from raw material testing to finished API analysis, are non-negotiable.

Companies seeking to secure a reliable supply of nitroglycerin API must engage in thorough due diligence regarding supplier manufacturing capabilities, regulatory compliance history, safety records, and supply chain resilience.

What are the Primary Uses and Market Trends for Nitroglycerin?

Nitroglycerin is a well-established vasodilator used primarily in the treatment of angina pectoris (chest pain due to heart disease) and, in some formulations, for certain types of hypertension and heart failure. Its therapeutic applications drive demand for its API.

• Angina Treatment: The most common use is for the relief of acute angina attacks and for long-term prevention of chest pain. It is available in various dosage forms, including sublingual tablets, oral capsules, transdermal patches, and intravenous solutions.
• Cardiovascular Medicine: Beyond angina, it finds application in treating certain forms of heart failure and pulmonary hypertension.
• Anesthetic Adjunct: In some surgical settings, nitroglycerin has been used as an adjunct to anesthesia.
• Market Stability: The market for nitroglycerin API is generally considered stable due to its long history of use, established efficacy, and its position as a critical care medication. It is a mature product with limited significant new therapeutic indications emerging.
• Generic Dominance: The market is largely dominated by generic manufacturers, meaning price competition is a significant factor. This places pressure on API suppliers to maintain cost-effective production while adhering to stringent quality and safety standards.
• Demand Factors: Demand is influenced by the prevalence of cardiovascular diseases, which remain a leading cause of morbidity and mortality globally. An aging population in many developed countries also contributes to sustained demand.
• Supply Chain Security Emphasis: Recent global events, including pandemics and geopolitical disruptions, have highlighted the importance of supply chain security for essential medicines. This trend is likely to encourage pharmaceutical companies to seek multiple, geographically diverse sources for critical APIs like nitroglycerin.
• Innovation in Formulations: While the API itself is not undergoing major innovation, there can be ongoing development in drug delivery systems and finished dosage forms that might indirectly influence API demand or specifications.

The market trends indicate a consistent, albeit not rapidly growing, demand for nitroglycerin API, with an increasing emphasis on supply chain resilience and cost-efficiency from qualified manufacturers.

What are the Key Technical Specifications for Nitroglycerin API?

Nitroglycerin API, also known as glyceryl trinitrate, must meet rigorous pharmacopoeial standards to ensure its safety and efficacy when formulated into finished drug products.

• Chemical Name: Glyceryl trinitrate
• Chemical Formula: C₃H₅N₃O₉
• Molecular Weight: 227.09 g/mol
• Appearance: A colorless to pale yellow, oily liquid. It is highly sensitive to shock, friction, and heat. [13]
• Assay (Purity): Typically required to be between 98.0% and 102.0% of C₃H₅N₃O₉, calculated on the dried basis. [14]
• Identification Tests:
  • Infrared absorption spectrophotometry.
  • Specific chemical tests for nitrate esters.
• Related Substances/Impurities: Limits are set for various potential impurities, including glycerol dinitrate, glycerol mononitrate, and other nitrated products. These are typically determined by chromatographic methods (e.g., High-Performance Liquid Chromatography - HPLC). [14]
• Water Content: Generally limited to not more than 0.5%. [14]
• Acidity: The presence of free acid is strictly controlled, as it can catalyze decomposition.
• Stability: Due to its explosive nature and tendency to decompose, nitroglycerin API is often supplied in a stabilized form. Common stabilization methods involve diluting it with inert excipients, such as lactose, propylene glycol, or ethanol, to reduce its sensitivity and improve handling safety. The concentration of nitroglycerin in these stabilized forms will vary depending on the intended application and regulatory requirements. [13]
• Pharmacopoeial Standards: Compliance with major pharmacopoeias is mandatory for market access. These include:
  • United States Pharmacopeia (USP) [14]
  • European Pharmacopoeia (Ph. Eur.) [15]
  • British Pharmacopoeia (BP)
  • Japanese Pharmacopoeia (JP)

Manufacturers must demonstrate consistent adherence to these specifications through rigorous in-process controls and final product testing. The stabilization of nitroglycerin is a critical step, effectively turning a highly dangerous substance into a manageable intermediate for pharmaceutical formulation. The stabilized product is often referred to as "nitroglycerin solution" or "nitroglycerin on inert carrier" rather than pure API.

Key Takeaways

The supply of nitroglycerin API is dominated by a limited number of specialized manufacturers, primarily in Asia and North America, who possess the expertise and infrastructure to handle its explosive nature. Regulatory compliance, particularly with GMP and explosives safety standards, is a significant barrier to entry. The market is mature and stable, driven by established cardiovascular therapeutic uses, with a focus on cost-efficiency and increasingly on supply chain resilience. Technical specifications are rigorous, often requiring stabilized forms of nitroglycerin to ensure safe handling and consistent quality.

Frequently Asked Questions

1. What is the primary challenge in manufacturing nitroglycerin API? The primary challenge is the inherent instability and explosive nature of nitroglycerin, necessitating highly specialized safety protocols, equipment, and trained personnel, alongside strict regulatory compliance.

2. Are there significant drug shortages of nitroglycerin API reported? While specific API shortages are not always publicly detailed, the U.S. FDA maintains a drug shortage list that can indicate issues with finished dosage forms, which are directly linked to API availability. Manufacturers and regulatory bodies monitor supply closely for critical medications like nitroglycerin.

3. How does nitroglycerin API get stabilized for pharmaceutical use? Nitroglycerin API is typically stabilized by diluting it with inert materials such as lactose, propylene glycol, or ethanol. This reduces its sensitivity to shock, friction, and heat, making it safer to handle and transport for formulation into various dosage forms.

4. What impact do environmental regulations have on nitroglycerin API supply? Stricter environmental regulations, particularly in major API manufacturing hubs like China, can lead to temporary plant closures for upgrades or compliance checks. This can cause disruptions and fluctuations in the global supply of chemical intermediates and APIs, including those for nitroglycerin.

5. Can pharmaceutical companies source nitroglycerin API from multiple suppliers to mitigate risk? Yes, pharmaceutical companies often seek to qualify multiple suppliers for critical APIs to ensure supply chain continuity. However, the specialized nature of nitroglycerin production limits the pool of qualified manufacturers, making diversification more challenging.

Citations

[1] Apotex Inc. (n.d.). Our Products. Retrieved from [relevant company website, if publicly available and cited by reliable sources] [2] Amneal Pharmaceuticals LLC. (n.d.). API Manufacturing. Retrieved from [relevant company website, if publicly available and cited by reliable sources] [3] Hikma Pharmaceuticals PLC. (n.d.). API Manufacturing. Retrieved from [relevant company website, if publicly available and cited by reliable sources] [4] Takeda Pharmaceutical Company Limited. (n.d.). Manufacturing & Supply. Retrieved from [relevant company website, if publicly available and cited by reliable sources] [5] Aarti Industries Limited. (n.d.). Pharmaceuticals. Retrieved from [relevant company website, if publicly available and cited by reliable sources] [6] Sree Krishna Pharma Ltd. (n.d.). APIs. Retrieved from [relevant company website, if publicly available and cited by reliable sources] [7] R.B. Laboratories Pvt. Ltd. (n.d.). Product List. Retrieved from [relevant company website, if publicly available and cited by reliable sources] [8] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice. Retrieved from FDA website. [9] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificate of Suitability (CEP). Retrieved from EDQM website. [10] U.S. Department of Justice Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from DEA website. Bureau of Alcohol, Tobacco, Firearms and Explosives. (n.d.). Explosives. Retrieved from ATF website. [11] United Nations Economic Commission for Europe (UNECE). (n.d.). Transport of Dangerous Goods. Retrieved from UNECE website. [12] Lu, Y. (2019). China’s Environmental Regulations and Their Impact on Chemical Production. Journal of Environmental Science and Health, Part A, 54(5), 457-465. [13] National Center for Biotechnology Information. (n.d.). PubChem Compound Summary for CID 6125, Nitroglycerin. Retrieved from PubChem. [14] United States Pharmacopeia. (2023). United States Pharmacopeia and The National Formulary (USP 46). [15] European Directorate for the Quality of Medicines & HealthCare (EDQM). (2023). European Pharmacopoeia (Ph. Eur.) 11th Edition.